TY - JOUR
T1 - Survival Trends of Metastatic Lung Cancer in California by Age at Diagnosis, Gender, Race/Ethnicity, and Histology, 1990-2014
AU - Li, Tianhong
AU - Pan, Kevin
AU - Ellinwood, Amy K.
AU - Cress, Rosemary D.
N1 - Funding Information:
KP received a Junior Investigator Award from the Chinese American Hematologist Oncologist Network (CAHON) for this work. The work was partially presented as an e-abstract in J Clin Oncol 2018; 36(15 Suppl):e18724. The collection of cancer incidence data used in this study was supported by the California Department of Public Health pursuant to California Health and Safety Code Section 103885; Centers for Disease Control and Prevention’s (CDC) National Program of Cancer Registries , under cooperative agreement 5NU58DP006344; the National Cancer Institute’s Surveillance, Epidemiology and End Results Program under contract HHSN261201800032I awarded to the University of California , San Francisco, contract HHSN261201800015I awarded to the University of Southern California , and contract HHSN261201800009I awarded to the Public Health Institute , Cancer Registry of Greater California. The ideas and opinions expressed herein are those of the author(s) and do not necessarily reflect the opinions of the State of California, Department of Public Health, the National Cancer Institute, and the Centers for Disease Control and Prevention or their Contractors and Subcontractors. This work was supported by the Personalized Cancer Therapy Gift Fund (TL) and the Biostatistics and Epidemiology Shared Resource funded by the UC Davis Comprehensive Cancer Center Support Grant (CCSG) awarded by the National Cancer Institute ( NCI P30CA093373 ) (RDC).
PY - 2021
Y1 - 2021
N2 - Background: We analyzed the survival trends for patients with metastatic lung cancer in California. Materials and Methods: We identified patients first diagnosed with primary lung cancer at distant (metastatic) stage in the California Cancer Registry between 1990 and 2014, with follow-up through end of 2015. Race/ethnicity was categorized into non-Hispanic white, non-Hispanic black, Hispanic, and Asian/Pacific Islander. One-year and 5-year relative survival rates were calculated overall and by age at diagnosis, gender, race/ethnicity, and histology during the study period. Joinpoint regression was used to evaluate the trends and to calculate the annual percentage changes (APCs). Results: A total of 186,156 adults were identified for analysis. Between 1990 and 2014, 1-year relative survival significantly improved from 18.4% to 29.4%, with most improvement observed between 1993 and 2012 (APC, 2.60%; 95% confidence interval, 2.41-2.79; P < .01). Five-year relative survival significantly improved from 2.2% to 5.0%, with an APC of 4.05% (95% confidence interval, 3.47-4.64; P < .01). All age groups experienced an improvement in survival rates. The greatest increases in relative survival were observed among females, Asian/Pacific Islanders, and patients with adenocarcinoma. Yearly survival rates increased for all histologic types over the study period, with adenocarcinoma having the most improvement after 2000. Conclusions: Survival for patients with metastatic lung cancer in California steadily improved during the 1990 to 2014 period, before the era of lung cancer screening and cancer immunotherapy. The greatest increase in relative survival was observed in those patients who have the most clinical benefit from the history- and biomarker-based precision oncology drugs during the study period.
AB - Background: We analyzed the survival trends for patients with metastatic lung cancer in California. Materials and Methods: We identified patients first diagnosed with primary lung cancer at distant (metastatic) stage in the California Cancer Registry between 1990 and 2014, with follow-up through end of 2015. Race/ethnicity was categorized into non-Hispanic white, non-Hispanic black, Hispanic, and Asian/Pacific Islander. One-year and 5-year relative survival rates were calculated overall and by age at diagnosis, gender, race/ethnicity, and histology during the study period. Joinpoint regression was used to evaluate the trends and to calculate the annual percentage changes (APCs). Results: A total of 186,156 adults were identified for analysis. Between 1990 and 2014, 1-year relative survival significantly improved from 18.4% to 29.4%, with most improvement observed between 1993 and 2012 (APC, 2.60%; 95% confidence interval, 2.41-2.79; P < .01). Five-year relative survival significantly improved from 2.2% to 5.0%, with an APC of 4.05% (95% confidence interval, 3.47-4.64; P < .01). All age groups experienced an improvement in survival rates. The greatest increases in relative survival were observed among females, Asian/Pacific Islanders, and patients with adenocarcinoma. Yearly survival rates increased for all histologic types over the study period, with adenocarcinoma having the most improvement after 2000. Conclusions: Survival for patients with metastatic lung cancer in California steadily improved during the 1990 to 2014 period, before the era of lung cancer screening and cancer immunotherapy. The greatest increase in relative survival was observed in those patients who have the most clinical benefit from the history- and biomarker-based precision oncology drugs during the study period.
KW - Annual percentage change
KW - California Cancer Registry
KW - Lung cancer
KW - Metastatic
KW - Relative survival rate
UR - http://www.scopus.com/inward/record.url?scp=85098935988&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85098935988&partnerID=8YFLogxK
U2 - 10.1016/j.cllc.2020.11.005
DO - 10.1016/j.cllc.2020.11.005
M3 - Article
C2 - 33414054
AN - SCOPUS:85098935988
JO - Clinical Lung Cancer
JF - Clinical Lung Cancer
SN - 1525-7304
ER -